Motevalli, M.H. et al. 2019. Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: A Systematic Review. International Pharmacy Acta. 2, 1 (Dec. 2019), 2e10:1–6. DOI:https://doi.org/10.22037/ipa.v2i1.24856.